npc

LY294002 (SF 1101) 是一种 PI3K 的广谱抑制剂，抑制 PI3Kα、PI3Kδ 和 PI3Kβ (IC50=0.5 0.57 0.97 μM)。LY294002 也是 DNA-PK 抑制剂 (IC50=1.4 μM) 和 CK2 抑制剂 (IC50=98 nM)。LY294002 可以激活凋亡和自噬。

LY-294002 hydrochloride (NSC 697286) 是一种合成的 PI3Kα δ β 分子抑制剂（IC50：0.5 0.57 0.97 μM，在无细胞试验中）；在溶液中比 Wortmannin 更稳定，也是自噬体形成的阻断剂。

RPR132595A is an active CPT-11 metabolite, it is generated by cytochrome P-450 3A4 (CYP3A4).

m-PEG-NPC (MW 20000) is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

NPC 567 is an antagonist of the bradykinin receptor.

NPC 567 acetate 是一种缓激肽 B2 拮抗剂，可用于治疗过敏性气道疾病的研究。

Npc 573 is a bioactive chemical.

NPC-15437 (盐酸盐) 是一种 PKC 的选择性抑制剂，与酶的调节域相互作用。

NPC-18915 is a benzofuran compound, inhibitor of neutophil activation.

NPC 17761 is a bradykinin receptor antagonist.

NPC 17731 is a bradykinin receptor antagonist.

NPC-14695 is a smooth muscle-selective muscarinic antagonist with bronchodilating activity.

NPC-16731 is a Bradykinin antagonist.

Npc 12626 is a N-methyl-D-aspartate receptor antagonist; NPC 17742, the (2R,4R,5S)-isomer, is the most potent isomer in the mixture NPC 12626.

NPC 15199 (FMOC-L-Leucine) 是选择性的PPARγ调节剂。它对 PPARγ 的激活效果比罗格列酮低，但二者最大效应相似。它能够改善正常、饮食诱导的葡萄糖不耐受和糖尿病 db db 小鼠的胰岛素敏感性，一定程度上能够诱导脂肪生成。

NPC26 是一种小分子线粒体干扰物，显示出抗肿瘤活性。它在CRC细胞系 (HCT-116、DLD-1和HT-29) 中表现出显著的抗增殖和细胞毒性。NPC26 能够破坏线粒体功能，导致线粒体通透性转换孔 (mPTP) 的开放和活性氧 (Reactive Oxygen Species) 的生成，进而诱导细胞死亡。此外，NPC26 可通过激活AMP活化蛋白激酶 (AMPK) 信号通路杀死CRC细胞。

(S)-VU0637120 是一种选择性的神经肽 Y（4）R变构拮抗剂，可用于研究代谢疾病。

CHF-2060 is a novel acetylcholinesterase inhibitor.

Tazemetostat HCl is a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity. EPZ-6438 induces apoptosis and differentiation specifically in SMARCB1-deleted MRT cells. Treatment of xenograft-bearing mice with EPZ-6438 leads to dose-dependent regression of MRTs with correlative diminution of intratumoral trimethylation levels of lysine 27 on histone H3, and prevention of tumor regrowth after dosing cessation. These data demonstrate the dependency of SMARCB1 mutant MRTs on EZH2 enzymatic activity and portend the utility of EZH2-targeted drugs for the treatment of these genetically defined cancers.

MI-888 is a potent MDM2 inhibitor (Ki = 0.44 nM) with a superior pharmacokinetic profile and enhanced in vivo efficacy. MI-888 is capable of achieving rapid, complete, and durable tumor regression in two types of xenograft models of human cancer with oral administration and represents the most potent and efficacious MDM2 inhibitor reported to date.

Ensituximab (NEO-102) 是一种准对 MUC5AC 变体的选择性 IgG1 单克隆抗体，具有抗肿瘤活性，抑制结直肠癌和胰腺癌。

RPR132595A (NPC) hydrochloride，CPT-11的活性代谢产物，由细胞色素P-450 3A4 (CYP3A4) 催化产生，经尿液排出体外。

Methazolamide-d6 is intended for use as an internal standard for the quantification of methazolamide by GC- or LC-MS. Methazolamide is a carbonic anhydrase inhibitor. It reduces intraocular pressure and cerebrospinal fluid flow in a rat model of glaucoma. Methazolamide reduces electroshock-induced seizures in rats with an ED50 value of 19.2 mg kg. It also inhibits production of reactive oxygen species (ROS) in a primary cortical neuron (PCN) cellular model of subarachnoid hemorrhage (SAH) and reduces cerebral edema in a mouse model of SAH.3 Methazolamide is larvicidal, with a 50% larvicidal concentration (LC50) value of 724 ppm, but has no activity when administered in the diet to adult A. aegypti. Formulations containing methazolamide have been used in the treatment of glaucoma.

GLGPNPCRKKCYKRDFLGR is a synthetic peptide featuring a sequence of 18 amino acids.